Merck & Co., Inc. (FRA:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 217.41B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 13.40 |
| Forward PE | 11.29 |
| Dividend | 2.91 (3.22%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 1,894 |
| Average Volume | 1,341 |
| Open | 90.20 |
| Previous Close | 90.50 |
| Day's Range | 90.00 - 91.00 |
| 52-Week Range | 65.50 - 99.50 |
| Beta | n/a |
| RSI | 73.98 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth Builders
Merck is a high-yield drug stock with a well-supported dividend payment. Enbridge is a boring energy stock with a hefty yield.
3 Non-AI Stocks to Buy: MRK, UPS, CVX
There are plenty of potential winners outside the world of AI.
Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?
One of Merck's key assets has just scored a significant phase 2 win, boosting investor confidence. This adds to other recent developments that could help the company overcome its challenges.
Merck: Excellence Across The Board
Merck (MRK) demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. MRK's innovation, highlighted by Keytruda's dominance a...
IHE: Pharma Powerhouse ETF Despite High Fees And Valuation
iShares U.S. Pharmaceuticals ETF offers growth and dividends from top holdings like LLY, JNJ, MRK with strong earnings and sector focus. See why IHE ETF is a buy.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Merck's Janumet to See 85% Price Reduction Under Medicare Negotiations
Merck's Janumet to See 85% Price Reduction Under Medicare Negotiations
Why Is Merck Stock Surging?
Merck (MRK)'s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings excee...
Merck to Participate in the Citi 2025 Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Citi 2025 Global Healthcare Conference.
Merck to Participate in the Citi 2025 Global Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of g...
Merck Reaches Analyst Target Price
In recent trading, shares of Merck & Co Inc (Symbol: MRK) have crossed above the average analyst 12-month target price of $103.30, changing hands for $105.66/share. When a stock reaches the target an ...
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference.
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of g...
Dow Movers: NVDA, MRK
In early trading on Tuesday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 2.8%. Year to date, Merck registers a 3.7% gain. And the w...
Kelun phase 3 ADC trial with Merck's Keytruda for NSCLC meets primary endpoint
Kelun Biotech's sac-TMT plus Merck's Keytruda shows significant progress in late-stage lung cancer trial. Read more here.
Dow Movers: PG, MRK
In early trading on Monday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 3.1%. Year to date, Merck registers a 1.3% gain. And the wo...
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.
MRK: Wells Fargo Upgrades Merck & Co to Overweight with New Price Target | MRK Stock News
MRK: Wells Fargo Upgrades Merck & Co to Overweight with New Price Target | MRK Stock News
Merck (MRK) to Showcase Hematology Advances at ASH 2025
Merck (MRK) to Showcase Hematology Advances at ASH 2025
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be pre...
FDA Approves First And Only ADC And PD-1 Inhibitor Regimen For Certain Patients With Bladder Cancer
(RTTNews) - Merck & Co., Inc. (MRK) announced that the FDA has approved KEYTRUDA and KEYTRUDA QLEX, each in combination with Padcev, as perioperative treatment for adult patients with muscle-invasive ...
Steven Cress' 6 Picks: 3 Dividend Income, 3 AI Growth Stocks
In volatile markets, Steve Cress recommends a barbell strategy: combining high-yield dividend stocks (MRK, PINE, OMF) with top AI growth stocks (MU, CLS, COMM). Seeking Alpha's quant system outperform...
Notable healthcare headlines for the week: Abbott, Medtronic, Merck and J&J in focus
Merck (MRK) Advises Against Tutanota's Mini-Tender Offer
Merck (MRK) Advises Against Tutanota's Mini-Tender Offer